Fuxiang Pharmaceutical (300497): Actively deploying CDMO and new materials based on APIs to embark on a new journey of growth
Fuxiang Pharmaceutical (300497) event comments: the price of sulbactam rebounded CDMO opens room for long-term growth
Fuxiang Pharmaceutical (300497): performance is expected to improve marginally and focus on the pace of new capacity release
Fuxiang Pharmaceutical (300497) semi-annual report comments: the company's performance is under short-term pressure on products under research + capacity release to boost growth
Fuxiang Pharmaceutical (300497): the Integration Strategy of Industry chain steadily promotes the Development of CDMO Business
Fuxiang Pharmaceutical Co., Ltd. (300497): 2020 performance before high and low after cooperation with Kailing Pharmaceutical to speed up the layout of CDMO
Fuxiang Pharmaceutical (300497) 2020 and 2021Q1 Financial report comments: price increase of core products CDMO cooperation adds new growth momentum
富祥药业(300497)2020年三季报点评:业绩符合预期 持续推进长期战略
富祥药业(300497)季报点评:疫情导致下游库存增加 影响Q3业绩表现
富祥药业(300497):Q3受停产检修等因素影响 未来产能将持续提升
Fuxiang Pharmaceutical (300497) incident review: The epidemic disrupted the third quarter's performance growth rate, and new production capacity was sequentially established for long-term growth
富祥药业(300497)季报点评:Q3去库存影响业绩 持续推进定增拓展产业一体化
富祥药业(300497):特色抗菌原料药生产企业 打造“医药中间体-原料药-制剂一体化”
富祥药业(300497):Β-内酰胺酶抑制剂龙头企业 业务拓展增添新的成长动能
富祥药业(300497):业绩表现良好 高端抗生素业务稳增长
富祥药业(300497):业绩超预期 产业链一体化稳步推进
富祥药业(300497):上半年业绩高增长 继续推进定增拓展产业链布局
富祥药业(300497):主力品种量价齐升 纵横双向拓展稳步推进
富祥药业(300497):抗菌素原料药持续高景气 公司业绩超预期
富祥药业(300497)半年报点评:半年度业绩表现亮眼 培南和抗病毒类产品需求旺盛
No Data